ELASMOGEN, the biopharmaceutical company, has announced it has secured follow-on equity investment from Deepbridge Capital totalling £2 million.

It takes Deepbridge’s total investment in Elasmogen to £3.15m. The funding will be used to accelerate the development of the company’s next generation biologics for site-specific delivery and treatment of diseases refractory to existing drug therapies.

Solomers are Elasmogen’s proprietary, humanised versions of drugs originally based on a protein found in nature which are key components of a shark’s immune system.